Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $3.3 million.

  • Lyell Immunopharma's Cash from Investing Activities rose 74.61% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.0 million, marking a year-over-year increase of 537.40%. This contributed to the annual value of $122.4 million for FY2024, which is 33.48% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Cash from Investing Activities stood at $3.3 million, which was down 73.52% from $12.6 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Cash from Investing Activities ranged from a high of $152.9 million in Q2 2023 and a low of -$144.9 million during Q3 2021.
  • For the 3-year period, Lyell Immunopharma's Cash from Investing Activities averaged around $35.6 million, with its median value being $32.2 million (2023).
  • In the last 5 years, Lyell Immunopharma's Cash from Investing Activities tumbled by 328.06% in 2021 and then surged by 511.18% in 2023.
  • Lyell Immunopharma's Cash from Investing Activities (Quarterly) stood at -$73.9 million in 2021, then soared by 163.16% to $46.6 million in 2022, then crashed by 315.85% to -$100.7 million in 2023, then spiked by 153.14% to $53.5 million in 2024, then spiked by 74.61% to $3.3 million in 2025.
  • Its Cash from Investing Activities was $3.3 million in Q3 2025, compared to $12.6 million in Q2 2025 and $69.5 million in Q1 2025.